Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy

Authors: BABATIN, M. A.¹; SANAI, F. M.²; SWAIN, M. G.¹

Source: Alimentary Pharmacology & Therapeutics, Volume 24, Number 5, September 2006 , pp. 813-820(8)

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Summary Background

Ursodeoxycholic acid is widely used as the standard therapy for the treatment of primary biliary cirrhosis and other cholestatic liver diseases. Although it has been shown to improve biochemical markers and delay disease progression, its effect upon fatigue and pruritus, is at best uncertain. Aim

To assess the safety and efficacy of methotrexate for treating symptomatic primary biliary cirrhosis patients who were biochemical partial responders or non-responders to ursodeoxycholic acid therapy. Methods

We treated eight consecutive primary biliary cirrhosis patients with methotrexate who were followed in a single hepatology clinical practice, who were symptomatic, and who had had an incomplete biochemical response to ursodeoxycholic acid therapy. Pruritus and fatigue were assessed at each clinic visit and graded from 0 (asymptomatic) to 4 (incapacitating). Results

The median dose of methotrexate was 13.75 mg/week (range 7.5-15) and the mean duration of methotrexate therapy was 49 months (range 11-126). At the end of follow-up pruritus in six of seven patients had improved, and fatigue in all patients had improved with the addition of methotrexate therapy (pruritus: baseline 2.9 ± 1.1 vs. end of treatment 0.6 ± 1.5, P ≤ 0.0175, and fatigue: baseline 3.0 ± 0.8, vs. end of treatment 1.0 ± 0.8, P ≤ 0.0023). Improvement in symptoms was associated with a significant improvement in biochemical markers of cholestasis. No significant adverse effects of methotrexate were documented. Conclusions

Methotrexate should be considered as a potential additive treatment for symptomatic primary biliary cirrhosis patients who are incomplete biochemical responders to ursodeoxycholic acid therapy.

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2036.2006.03048.x

Affiliations: 1: Liver unit, University of Calgary, AB, Canada 2: London Health Sciences Center, University of Western Ontario, London, ON, Canada

Publication date: 2006-09-01

Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy

Buy & download fulltext article:

Tools

Key

Text size:

Useful pages